Most people are expected to contract RSV by the age of two, though no vaccine has yet to be approved.
to public health nonprofit PATH, there are 11 RSV vaccines being studied in trials—four are designed for infants and seven are for older adults.to findings published on Wednesday, Pfizer’s RSV vaccine is 82% effective at protecting infants from severe infections when given to pregnant mothers in the second half of their pregnancies.
Almost all children will have had an RSV infection by their second birthday, and most infections go away on their own,Dr. Barney Graham, a senior adviser for global health equity at Morehouse School of Medicine, told NBC News he believes all the vaccines “are going to work well enough to be approved, depending on the side effect profiles.”
Norge Siste Nytt, Norge Overskrifter
Similar News:Du kan også lese nyheter som ligner på denne som vi har samlet inn fra andre nyhetskilder.
FDA approves overdose reversal drug, first responders say it could save livesDoctors and first responders say making the opioid reversal drug Narcan available over the counter could help lower the number of people dying from overdoses.
Les mer »
Chinese startup becomes first in history to reach orbit on first attemptChinese private space firm Space Pioneer became the first startup to successfully reach orbit on its first attempt this past weekend, a report from SpaceNews reveals. Find out more at 🚀 engineering interestingengineering
Les mer »
Late-stage RSV vaccine trials show 'exciting promise,' some scientists say | CNNA Pfizer vaccine to protect older adults and infants from respiratory syncytial virus (RSV) infection has shown what some scientists are calling “exciting” promise in late-stage trials.
Les mer »
Pfizer RSV vaccine 82% effective vs severe infection in infants, final data showsPfizer Inc's experimental respiratory syncytial virus (RSV) vaccine was 82% effective in preventing severe infections in infants when given to expecting mothers in the second half of their pregnancy, according to trial details published on Wednesday that confirm preliminary data from the study.
Les mer »
Pfizer RSV vaccine 82% effective vs severe infection in infants, final data shows (April 5)Pfizer Inc's experimental respiratory syncytial virus (RSV) vaccine was 82% effective in preventing severe infections in infants when given to expecting mothers in the second half of their pregnancy, according to trial details published on Wednesday that confirm preliminary data from the study.
Les mer »